Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Adam O Brien

Orthopaedic Surgery Pflugerville, TX Medical Doctor

NPI 1013283860 CMS profile 8521904

2600 E Pflugerville Pkwy Ste 200, Pflugerville, TX 78660

Open in the dashboard

General payments

$17,705

84 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam O Brien of Pflugerville, TX is reported in the CMS Open Payments database as having received $17,705 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $201 4
2024 General $457 9
2023 General $2,335 12
2022 General $5,121 26
2021 General $5,827 24
2020 General $3,763 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam O Brien
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Adam O Brien were reported at $201. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Adam O Brien Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $3,763 $312 $75–$1,860 $114
2021 $5,827 $520 $117–$2,495 $132
2022 $5,121 $598 $128–$2,731 $149
2023 $2,335 $461 $128–$2,264 $160
2024 $457 $497 $134–$2,475 $164
2025 $201 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Pylant Medical $6,015 6 payments
  2. Medinc of Texas $4,663 4 payments
  3. Stryker Corporation $3,202 28 payments
  4. Arthrex, Inc. $2,386 18 payments
  5. Smith+Nephew, Inc. $985 17 payments
  6. Core Surgical Group $196 4 payments
  7. Exactech, Inc. $80 1 payment
  8. Vericel Corporation $54 1 payment
  9. DePuy Synthes Sales Inc. $31 1 payment
  10. Innovation Technologies Inc $29 1 payment
  11. Other $65 3 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Education $12,013 11 payments
  2. Travel and Lodging $3,077 11 payments
  3. Food and Beverage $2,615 62 payments
Products named General payments · program years 2020–2025
  1. MAKO $2,421 10 payments
  2. NOVOSTITCH PRO $578 5 payments
  3. REGENETEN Shoulder $462 3 payments
  4. HEALICOIL PK Shoulder $240 2 payments
  5. INSPACE $162 3 payments
  6. ARTHREX $149 1 payment
  7. TRIGEN INTERTAN $134 1 payment
  8. EVOS $134 1 payment
  9. TRIATHLON $123 2 payments
  10. ALPHAVENT $103 2 payments
  11. Other $1,119 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

93

Median for Orthopedic Surgery: 203

Drug cost

$392

Median for Orthopedic Surgery: $1,433

Branded share of claims

16.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 13 $109
Meloxicam Generic 40 $100
Oxycodone Hcl Generic 14 $74
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $66
Ondansetron Hcl Generic 11 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$84,121

Of which drugs: $19,741

Medicare patients

262

Average age 73

Services billed

1,340

153 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 26%
Ischemic heart disease 24%
Depression 23%
Chronic kidney disease 22%
Cancer 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 31 40 $16,314
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 78 337 $252

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record